UBS has downgraded Inspire Medical Systems Inc (INSP) to Neutral from Buy, signaling increased caution regarding the company's outlook. The action, taken on September 21, 2025, comes as Inspire's current stock price stands at $89.88.
This downgrade suggests potential concerns about competitive pressures, market conditions, or execution risks that could affect the company's performance. Inspire Medical Systems, headquartered in Golden Valley, Minnesota, specializes in developing minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire therapy is an FDA-approved neurostimulation technology that delivers effective treatment for moderate to severe cases of OSA.
Inspire Medical boasts a market capitalization of $2.4 billion, with a P/E ratio of 53.89 and an EPS of 1.47. The company is scheduled to announce its upcoming earnings on August 3, 2026, with an estimated EPS of $0.33 and expected revenue of $249.0 million.
Analyst ratings and price targets provide insights based on research and financial models. While they can be informative, it's crucial for investors to consider various factors, including company fundamentals and industry trends, before making investment decisions. Analyst opinions can shift as new information emerges, highlighting the dynamic nature of market assessments.